PSMA-targeted therapy – PROSTATE WARRIORS – The latest news about prostate cancer

PSMA-1-DOTA: A New Ligand to Make Prostate Cancer Radioligand Therapy More Targeted

January 9, 2026/in Antibody Radioconjugate, Preclinical Research/by Max

PSMA-targeted radioligand therapy (RLT) has transformed treatment for end-stage prostate cancer, offering strong tumor control in patients who have exhausted other options. However, these therapies frequently cause severe salivary gland damage, leading to debilitating dry mouth that often forces patients to stop treatment early. To overcome this, researchers at Case Western Reserve University developed PSMA-1-DOTA, […]

HRS-4357, a Novel PSMA-targeted Radiologand Therapy Phase 3 Trial

January 1, 2026/in Clinical Trial, Metastatic, Phase 3/by Max

HRS-4357, a novel PSMA-targeted radiopharmaceutical, is poised to enter a landmark Phase III clinical trial targeting metastatic castration-resistant prostate cancer (mCRPC). The trial, received approval from China’s National Medical Products Administration on December 23, 2025, and plans to enroll 370 patients across multiple centers in China. This randomized, open-label, controlled study will directly compare HRS-4357 […]

MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors

December 12, 2025/in Clinical Trial, Metastatic, Phase 1, Phase 2/by Max

MHB048C is an investigational antibody–drug conjugate designed to target prostate‑specific membrane antigen (PSMA) on tumor cells and selectively deliver a DNA topoisomerase I–inhibiting cytotoxic payload. By combining a PSMA‑directed antibody with a potent payload, the drug aims to exploit the high and relatively restricted expression of this surface antigen in advanced prostate cancer and in […]